Barbara W. Bodem - 17 Aug 2022 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 17 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2022, 16:37:04 UTC
Prior SEC filing: 09 Jun 2022
Next SEC filing: 18 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Paolo Tombesi, Attorney-in-Fact

Key filing fact

Barbara W. Bodem filed Form 4 for Turning Point Therapeutics, Inc. on 17 Aug 2022.

Key facts

This page summarizes Barbara W. Bodem's Form 4 filing for Turning Point Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2022, 16:37.

Change

Previous filing in this sequence was filed on 09 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TPTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -14,995
Change %: -100%
Price
Shares after: 0
Date: 17 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,995
Exercise price: $94.59
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Barbara W. Bodem is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

Footnote F2

At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.